Does the dose of methotrexate influence the rate of relapse in patients with Wegener's granulomatosis? Commentary

Nature Clinical Practice Rheumatology

Volumn 4, Issue 1, 2008, Pages 12-13

  Molloy, Eamonn S ^a   Langford, Carol A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE;

BRAIN TUMOR; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLOMERULONEPHRITIS; HUMAN; HYPERTENSION; LEUKOPENIA; LOADING DRUG DOSE; LUNG DISEASE; LUNG HEMORRHAGE; MAINTENANCE THERAPY; PERIPHERAL NEUROPATHY; PILOT STUDY; PRIORITY JOURNAL; RELAPSE; SHORT SURVEY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS;

EID: 38049053745     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0675     Document Type: Short Survey

References (5)

1. Sneller MC et al. (1995) An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 38: 608-613
2. Langford CA et al. (1999) A staged approach to the treatment of Wegener's granulomatosis: Induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 42: 2666-2673
3. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group (2005) Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352: 351-361
4. De Groot K et al. (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculits. Arthritis Rheum 52:2461-2469
5. Metzler C et al. (2004) Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 43: 315-320